European Psychiatry - Volume 41 - April 2017

172 / 916

S168 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S106–S169
ineffective or cause side effects. Polymorphic variants of genes that
code CYP450 enzymes cause differences in their activity and there-
fore in efficacy and safety of drugs that are metabolized by them.
Aim of the study Determine whether pharmacogenetic testing
of CYP2D6, CYP2C19 and CYP2C9 polymorphism would have had
influence on selected patients’ treatment courses.
Methods Five patients that were diagnosed for treament-
resistant mood disorders in Vilnius university hospital Santariskiu
clinics centre of neurology, department of psychiatry were invited
to give blood samples for genetic testing retrospectively. Patients’
CYP2C19, CYP2D6 and CYP2C9 enzymes genetic polymorphism
results were compared with previous empirical pharmacological
treatment courses of these patients.
Results In four out of five cases significant polymorphism of
CYP2C19 enzyme allele was detected. In all of these cases 1*/2*
variant, that conditions intermediate metabolizer phenotype, was
identified. Alterations in CYP2D6 and CYP2C19 regions were not
found. In three cases the presence of varied genetic variant
could have been clinically relevant. In two of these cases Ser-
traline and valproates, that are both metabolized by CYP2C19
enzyme, were taken by patients and side effects were observed.
Unsuccessful treatment was repeated without effect, both in
clinical and outpatient environment. Continuous rehospitaliza-
tion took place until appropriate empirical treatments were
established.
Conclusions Pharmacogenetic testing could have had influence
on treatment choices for three out of five selected patients leading
to less side effects and rehospitalizations.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0187
Mthfr Allele distribution in Romanian
schizophrenia patients
B. Nemes ∗ ozman
Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca,
Department of Medical Psychology, Cluj-Napoca, Romania
∗ Corresponding author.
Introduction Currently available data on the aetiology of
schizophrenia suggests a major involvement of epigenetic mecha-
nisms. One such mechanism could be the alteration of activation
and silencing of genes, which involves DNA methylation and
de-methylation. The main limiting enzyme involved in the methyl-
donor cycle is methylene-tetra-hydro-folate-reductase (MTHFR),
and the most frequently observed mutation in the MTHFR gene,
altering its activity, is the C677 T mutation.
Aim In the present study, we investigated the frequency of
MTHFR C677 T mutation and total plasma homocysteine (tHcy)
concentrations in a sample of Romanian schizophrenia patients as
compared to healthy controls.
Methods Seventy schizophrenia patients (35% females) with a
mean age of 38.8 ± 20.5 years and 50 healthy controls (50% females)
with a mean age of 36.3 ± 11.6 years were included. MTHFR geno-
type was determined through polymerase chain reaction and tHcy
levels were determined through reversed phase high-pressure liq-
uid chromatography.
Results Schizophrenia patients, registered higher frequency
of the T allele, with the CC genotype observed in 39.4% of
them, as compared to a frequency of 60.6% in the control
group (P= 0.002–Fisher’s exact test). tHcy concentrations did
not differ between the two groups (10.7 ± 4.2 vs. 11.2 ±4.1,
P > 0.005–Mann–Whitney U test).
Conclusions Romanian schizophrenia patients have a signifi-
cantly higher frequency of theMTHFRC677 Tmutation, butwithout
significant effect on tHcy concentrations.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0188
Influence of 5-HTR2C polymorphisms
on metabolic syndromes in Thai
schizophrenia patients
A. Puangpetch ∗ a Nakorn Unaharassamee
C. Sukasem
1 Pathology service, Faculty of Medicine, Ramathibodi hospital,
Mahidol University, Bangkok, Thailand
2 Psychiatry, Somdet Chaopraya Institute of Psychiatry, Bangkok,
Thailand
∗ Corresponding author.
Introduction Metabolic syndrome is a significant problem in
the schizophrenia patients. Previous research demonstrated that
single nucleotide polymorphisms in the serotonin 2C receptor
(5HTR2C) genes are associated with metabolic syndrome related
to schizophrenia patients taking atypical anti-psychotic drugs.
This study aimed to investigate whether the effect of 3 SNPs in
5HTR2C gene on the presence of the metabolic syndrome in Thai
schizophrenia patients.
Method We conducted a cross-sectional study and 154 patients
were recruited. The schizophrenia patients were identified from a
diagnostic and statistical manual of mental disorders, 4th edition,
(DSM-IV) and criterion and determined the metabolic syndrome
according to the 2005 international diabetes federation (IDF)
Asia criteria. Patients were genotyped for the 5HTR2C rs51,8147,
rs126,881,02, rs128,367,71 polymorphisms.
Results The preliminary analysis from 154 patients showed the
metabolic syndrome prevalence was 38.73%, with 46.50% in male
and 53.48% in female patients. The results showed that the patients
who have heterozygous and homozygous variant on 5HTR2C gene
(rs518,147 and rs126,881,02) showed a significant difference in the
presence of metabolic syndrome when compare with patients who
carry homozygous wild type (P = 0.007), especially in male patients
(P = 0.002). The association between 5HTR2C polymorphisms and
metabolic syndrome was found in male patients but not found in
female patients.
Conclusion These findings suggest that 5HTR2C genotypes are
associated with the metabolic syndrome in patients taking atypical
anti-psychotics. However, themetabolic syndrome results fromthe
multigenetic effects. The further studies should focus on the other
genes, which were involved in metabolic syndrome.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0189
Prevalence of the CYP2D6*10 (C100 T)
polymorphism in psycho-neurological
patients in North-Western and
Siberian regions of the Russia
N.A. Shnayder . Nasyrova . Lipatova
V.V. Teplyashina , K.A. Sosina , N.A. Sivakova ∗,
E.N. Bochanova , D.V. Dmitrenko , I.P. Artyuhov ,
N.G. Neznanov
1 Voyno-Yasenetsky, the Department of Medical Genetics and Clinical
Neurophysiology, The Krasnoyarsk State medical University named
after Prof. V.F., Krasnoyarsk, Russia
2 The Department of Personalized Psychiatry and Neurology, St.
Petersburg Psychoneurological Research Institute named after V.M.
Bekhterev, Saint-Petersburg, Russia